JP2008545393A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545393A5
JP2008545393A5 JP2008512471A JP2008512471A JP2008545393A5 JP 2008545393 A5 JP2008545393 A5 JP 2008545393A5 JP 2008512471 A JP2008512471 A JP 2008512471A JP 2008512471 A JP2008512471 A JP 2008512471A JP 2008545393 A5 JP2008545393 A5 JP 2008545393A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
polynucleotide
host cell
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008512471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545393A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/019088 external-priority patent/WO2007044083A2/en
Publication of JP2008545393A publication Critical patent/JP2008545393A/ja
Publication of JP2008545393A5 publication Critical patent/JP2008545393A5/ja
Pending legal-status Critical Current

Links

JP2008512471A 2005-05-18 2006-05-17 進歩したインターフェロンαポリペプチド Pending JP2008545393A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68276905P 2005-05-18 2005-05-18
PCT/US2006/019088 WO2007044083A2 (en) 2005-05-18 2006-05-17 Evolved interferon-alpha polypeptides

Publications (2)

Publication Number Publication Date
JP2008545393A JP2008545393A (ja) 2008-12-18
JP2008545393A5 true JP2008545393A5 (enExample) 2009-06-25

Family

ID=37943260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008512471A Pending JP2008545393A (ja) 2005-05-18 2006-05-17 進歩したインターフェロンαポリペプチド

Country Status (11)

Country Link
US (1) US7619067B2 (enExample)
EP (1) EP1888633A4 (enExample)
JP (1) JP2008545393A (enExample)
KR (1) KR20080019619A (enExample)
CN (1) CN101501068A (enExample)
AU (1) AU2006299901A1 (enExample)
BR (1) BRPI0609809A2 (enExample)
CA (1) CA2607651A1 (enExample)
IL (1) IL186880A0 (enExample)
MX (1) MX2007014524A (enExample)
WO (1) WO2007044083A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537762A (ja) 1999-01-05 2002-11-12 トラスティーズ オブ ボストン ユニバーシティ 改良型核酸クローニング
US7435562B2 (en) 2000-07-21 2008-10-14 Modular Genetics, Inc. Modular vector systems
ATE540110T1 (de) 2004-11-11 2012-01-15 Modular Genetics Inc Oligonukleotid-leiterkonstruktion und system zur erzeugung von molekularer vielfalt
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CN101636414B (zh) * 2007-09-04 2012-02-15 厦门伯赛基因转录技术有限公司 聚乙二醇修饰的干扰素α2b及其制备方法和应用
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2009129616A1 (en) 2008-04-21 2009-10-29 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
EP2440251A4 (en) 2009-06-09 2013-01-16 Defyrus Inc INTERFERON ADMINISTRATION FOR PROPHYLAXIS AGAINST PATHOGEN INFECTION OR TREATMENT OF PATHOGEN INFECTION
CN101921330B (zh) * 2010-06-02 2013-07-17 北京三元基因工程有限公司 重组人干扰素α1b突变体及其制备方法
PL2822575T3 (pl) * 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
HUE065662T2 (hu) 2015-09-15 2024-06-28 Ilc Therapeutics Ltd Készítmények és eljárások betegségek kezelésére
CN108733975B (zh) * 2018-03-29 2021-09-07 深圳裕策生物科技有限公司 基于二代测序的肿瘤克隆变异检测方法、装置和存储介质
CN111499718B (zh) * 2019-01-30 2022-06-14 复旦大学 人α干扰素受体结合相关位点突变体及其用途
CN114853875B (zh) * 2019-06-13 2023-07-25 江苏科技大学 鸭α干扰素及其突变体、制备方法和应用
PL4121092T3 (pl) * 2020-03-16 2024-08-19 Ilc Therapeutics Ltd Hybrydowe interferony do leczenia zakażeń wirusowych
EP3901168A1 (en) * 2020-04-21 2021-10-27 Universität Duisburg-Essen Interferon alpha 2 variants and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
ES8302778A1 (es) 1980-11-10 1983-02-01 Genentech Inc Un procedimiento para producir un polipeptido antiviral.
US4414150A (en) 1980-11-10 1983-11-08 Genentech, Inc. Hybrid human leukocyte interferons
WO1983002461A1 (en) 1982-01-19 1983-07-21 Cetus Corp Multiclass hybrid interferons
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
ES2128348T3 (es) 1990-10-17 1999-05-16 Amgen Inc Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5780021A (en) * 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
PT741577E (pt) 1994-03-07 2003-03-31 Imperial College Utilizacao do subtipo de interferao alfa 8 na preparacao de medicamentos para tratar infeccoes virais do figado
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
AU775937B2 (en) 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2000052153A2 (en) 1999-03-02 2000-09-08 Maxygen, Inc. Method to identify ligands for orphan receptors
KR20020018197A (ko) 1999-05-19 2002-03-07 추후보정 Fc 융합 단백질로서의 인터페론-알파 단백질의 발현 및분비
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
AU8001300A (en) 1999-10-07 2001-05-10 Maxygen, Inc. Ifn-alpha homologues
NZ522847A (en) 2000-05-16 2004-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2002044197A2 (en) 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
KR100459105B1 (ko) 2001-02-15 2004-12-03 선바이오(주) 변형된 인터페론-알파 2a 및 2b, 그리고 이들과 PEG유도체와의 배합체
MXPA05005178A (es) 2002-11-15 2005-07-22 Hoffmann La Roche Isomeros posicionales del interferon alfa 2a (ifn) pegilado con una porcion de polietilenglicol grande (peg).
NZ540043A (en) 2002-11-18 2007-11-30 Maxygen Inc Isolated or recombinant Interferon-alpha polypeptides and conjugates
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates

Similar Documents

Publication Publication Date Title
JP2002510494A5 (enExample)
JP2006149406A5 (enExample)
JP2008507298A5 (enExample)
JP2025184979A5 (enExample)
JP2009540801A5 (enExample)
JP2013027391A5 (enExample)
JPH09322781A5 (enExample)
IL309801B1 (en) Use of protein domains interacting with the nucleosome to enhance targeted genome modification
JP2005120106A5 (enExample)
JP2013501038A5 (enExample)
JP2003516731A5 (enExample)
Buckland et al. Fusion glycoprotein of measles virus: nucleotide sequence of the gene and comparison with other paramyxoviruses
JP2014504851A5 (enExample)
JP2017513479A5 (enExample)
JP2009268467A5 (enExample)
JP2004532014A5 (enExample)
JP2006506097A5 (enExample)
CN115427071A (zh) 包含ltb和病原性抗原的组合物及其用途
JP2012516140A5 (enExample)
JP2005509420A5 (enExample)
JP2002539781A5 (enExample)
CN107353346A (zh) 一种由猪白蛋白与猪干扰素γ组成的融合蛋白及其制备方法和一种重组猪长效干扰素γ
Rueda et al. Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles
JPWO2020027010A5 (enExample)
JP2010514698A5 (enExample)